CIK 0001395937 · Large accelerated filer
Syndax Pharmaceuticals Inc
Sign in to watch- Ticker
- SNDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320162505
- Phone
- 781-419-1400
- Business address
- 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $113,716
- in 1 filing, $114K under 10b5-1 plans
Net −$113,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-09-16 | Morrison Briggs President, Head of R&D | Sale | −71,966 | $23.22 | $1.7M | 17,836 |
| 2022-09-16 | Morrison Briggs President, Head of R&D | Option exercise | +53,034 | $10.90 | $578K | 70,870 |
| 2022-09-16 | Morrison Briggs President, Head of R&D | Sale | −53,034 | $23.22 | $1.2M | 17,836 |
| 2022-09-16 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −53,034 | 0 | ||
| 2022-09-16 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −71,966 | 0 | ||
| 2022-09-16 | Podlesak Dennis Director | Option exercise | +5,419 | $6.32 | $34K | 81,182 |
| 2022-09-16 | Podlesak Dennis Director | Sale | −5,419 | $23.43 | $127K | 75,763 |
| 2022-09-16 | Podlesak Dennis Director | Option exercise | +6,556 | $6.35 | $42K | 82,319 |
| 2022-09-16 | Podlesak Dennis Director | Sale | −6,556 | $23.43 | $154K | 75,763 |
| 2022-09-16 | Podlesak Dennis Director | Option exercise · Stock Options (Right to buy) | −6,556 | 0 | ||
| 2022-09-16 | Podlesak Dennis Director | Option exercise · Stock Options (Right to buy) | −5,419 | 0 | ||
| 2022-09-15 | Morrison Briggs President, Head of R&D | Option exercise | +66,775 | $7.20 | $481K | 84,611 |
| 2022-09-15 | Morrison Briggs President, Head of R&D | Sale | −66,775 | $24.20 | $1.6M | 17,836 |
| 2022-09-15 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −66,775 | 0 | ||
| 2022-09-15 | Podlesak Dennis Director | Option exercise | +66,840 | $6.32 | $422K | 142,603 |
| 2022-09-15 | Podlesak Dennis Director | Sale | −66,840 | $24.20 | $1.6M | 75,763 |
| 2022-09-15 | Podlesak Dennis Director | Option exercise · Stock Options (Right to buy) | −66,840 | 0 | ||
| 2022-09-14 | Morrison Briggs President, Head of R&D | Option exercise | +87,645 | $7.20 | $631K | 105,481 |
| 2022-09-14 | Morrison Briggs President, Head of R&D | Sale | −87,645 | $23.80 | $2.1M | 17,836 |
| 2022-09-14 | Morrison Briggs President, Head of R&D | Option exercise · Stock Options (Right to buy) | −87,645 | 0 |
Page 12 of 15 · 290 trades